RESUMEN
Self-adjuvanting vaccines, wherein an antigenic peptide is covalently bound to an immunostimulating agent, have been shown to be promising tools for immunotherapy. Synthetic Toll-like receptor (TLR) ligands are ideal adjuvants for covalent linking to peptides or proteins. We here introduce a conjugation-ready TLR4 ligand, CRX-527, a potent powerful lipid A analogue, in the generation of novel conjugate-vaccine modalities. Effective chemistry has been developed for the synthesis of the conjugation-ready ligand as well as the connection of it to the peptide antigen. Different linker systems and connection modes to a model peptide were explored, and in vitro evaluation of the conjugates showed them to be powerful immune-activating agents, significantly more effective than the separate components. Mounting the CRX-527 ligand at the N-terminus of the model peptide antigen delivered a vaccine modality that proved to be potent in activation of dendritic cells, in facilitating antigen presentation, and in initiating specific CD8+ T-cell-mediated killing of antigen-loaded target cells in vivo. Synthetic TLR4 ligands thus show great promise in potentiating the conjugate vaccine platform for application in cancer vaccination.
Asunto(s)
Vacunas contra el Cáncer/síntesis química , Glucosamina/análogos & derivados , Lípido A/análogos & derivados , Compuestos Organofosforados/química , Ovalbúmina/química , Receptor Toll-Like 4/inmunología , Adyuvantes Inmunológicos , Animales , Vacunas contra el Cáncer/química , Vacunas contra el Cáncer/inmunología , Citocinas/inmunología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Glucosamina/química , Glucosamina/inmunología , Inmunoglobulina G/sangre , Ligandos , Activación de Linfocitos/efectos de los fármacos , Ratones , Compuestos Organofosforados/inmunología , Ovalbúmina/inmunología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Vacunas ConjugadasRESUMEN
CRX-527 belongs to a new family of synthetic lipid A mimetics, the aminoalkyl glucosaminide 4-phosphates, which are considered as potential vaccine adjuvants or stand-alone immunotherapeutics to harness innate immune defenses. Since natural lipid A from bacterial LPS depends on membrane-bound (mCD14) or soluble CD14 for its TLR4 ligand activity, we investigated the involvement of both forms of CD14 in the responses elicited by CRX-527. First, we found that CRX-527 induces NF-kappaB and interferon regulatory factor-3 (IRF-3) activation in human embryonic kidney cells transfected with TLR4 and MD-2 genes alone, whereas the responses to LPS require either co-transfection of the gene encoding mCD14 or addition of soluble CD14. We then observed that monocyte-derived DC, which are devoid of mCD14 respond to CRX-527 but not to LPS in serum-free medium. Furthermore, we found that, in contrast to LPS, CRX-527 induces the production of cytokines in whole blood of a patient with paroxysmal nocturnal hemoglobinuria, a disease in which mCD14-dependent responses are defective. Finally, we demonstrated that splenocytes from CD14-deficient mice produce cytokines in response to CRX-527 but not to LPS. We conclude that the lipid A mimetic CRX-527 does not require the CD14 co-receptor to elicit TLR4-mediated responses.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Glucosamina/análogos & derivados , Lípido A/inmunología , Receptores de Lipopolisacáridos/inmunología , Compuestos Organofosforados/inmunología , Compuestos Organofosforados/farmacología , Transducción de Señal/inmunología , Animales , Biomimética , Línea Celular , Citocinas/biosíntesis , Citocinas/inmunología , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Glucosamina/inmunología , Glucosamina/farmacología , Humanos , Antígeno 96 de los Linfocitos/biosíntesis , Antígeno 96 de los Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Receptor Toll-Like 4/biosíntesis , Receptor Toll-Like 4/inmunología , TransfecciónRESUMEN
An effective intranasal (i.n.) vaccine against pneumonic plague was developed. The formulation employed two synthetic lipid A mimetics as adjuvant combined with Yersinia pestis-derived V- and F1-protective antigens. The two nontoxic lipid A mimetics, classed as amino-alkyl glucosaminide 4-phosphates (AGPs) are potent ligands for the Toll-like receptor (TLR) 4. Using a murine (BALB/c) pneumonic plague model, we showed a single i.n. application of the vaccine provided 63% protection within 21 days against a Y. pestis CO92 100 LD50 challenge. Protection reached 100% by 150 days. Using a homologous i.n. 1 degrees /2 degrees dose regimen, with the boost administered at varying times, 63% protection was achieved within 7 days and 100% protection was achieved by 21 days after the first immunization. Little or no protection was observed in animals that received antigens alone, and no protection was observed when the vaccine was administered to BALB/c TLR4 mutant mice. Vaccine-induced serum IgG titers to F1 and V-antigen were reflected in high titers for IgG1 and IgG2a, the latter reflecting a bias for a cell-mediated (TH1) immune response. This intranasal vaccine showed 90% protection in Sprague-Dawley rats challenged with 1000 LD50. We conclude that lipid A mimetics are highly effective adjuvants for an i.n. plague vaccine.
Asunto(s)
Adyuvantes Inmunológicos , Glucosamina , Lípido A/inmunología , Imitación Molecular , Vacuna contra la Peste/inmunología , Peste/prevención & control , Administración Intranasal , Animales , Anticuerpos Antibacterianos/sangre , Modelos Animales de Enfermedad , Femenino , Glucosamina/administración & dosificación , Glucosamina/análogos & derivados , Glucosamina/síntesis química , Glucosamina/inmunología , Humanos , Lípido A/química , Masculino , Ratones , Ratones Endogámicos BALB C , Peste/inmunología , Peste/microbiología , Peste/mortalidad , Vacuna contra la Peste/administración & dosificación , Vacuna contra la Peste/química , Ratas , Ratas Sprague-Dawley , Receptor Toll-Like 4/genética , Receptor Toll-Like 4/metabolismo , Yersinia pestis/inmunología , Yersinia pestis/patogenicidadRESUMEN
BACKGROUND: There is concern that shrimp-allergic individuals may react to glucosamine-containing products as shrimp shells are a major source of glucosamine used for human consumption. OBJECTIVE: The purpose of this study was to determine whether shrimp-allergic individuals can tolerate therapeutic doses of glucosamine. METHODS: Subjects with a history of shrimp allergy were recruited and tested for both shrimp reactivity via a prick skin test and shrimp-specific IgE by an ImmunoCAP assay. Fifteen subjects with positive skin tests to shrimp and an ImmunoCAP class level of two or greater were selected for a double-blind placebo-controlled food challenge (DBPCFC) using glucosamine-chondroitin tablets containing 1,500 mg of synthetically produced (control) or shrimp-derived glucosamine. Immediate reactions, including changes in peak flow and blood pressure, and delayed reactions (up to 24 h post-challenge) via questionnaire were noted and assessed. RESULTS: All subjects tolerated 1,500 mg of both shrimp-derived or synthetic glucosamine without incident of an immediate hypersensitivity response. Peak flows and blood pressures remained constant, and no subject had symptoms of a delayed reaction 24 h later. CONCLUSION: This study demonstrates that glucosamine supplements from specific manufacturers do not contain clinically relevant levels of shrimp allergen and therefore appear to pose no threat to shrimp-allergic individuals.
Asunto(s)
Alérgenos/inmunología , Decápodos , Hipersensibilidad a los Alimentos/inmunología , Glucosamina/inmunología , Adulto , Animales , Suplementos Dietéticos , Método Doble Ciego , Femenino , Humanos , Hipersensibilidad Tardía/inmunología , Hipersensibilidad Inmediata/inmunología , Masculino , Persona de Mediana Edad , Pruebas CutáneasRESUMEN
Patients with the acquired immunodeficiency syndrome (AIDS) are susceptible to a variety of opportunistic pathogens which require intact cellular immunity for control and eradication. We evaluated interleukin 1 and 2 production in 12 homosexual men without AIDS but with evidence of altered cell-mediated immunity and serologic evidence of infection with human T-cell lymphotrophic virus type III (HTLV-III), the etiologic agent of AIDS and found production of both factors diminished compared to heterosexual controls. Therafectin (SM-1213) is a new agent which selectively activates macrophages and stimulated interleukin 1 production in vitro. Therafectin was administered to these same 12 patients in a double-blind, placebo controlled trial. We failed to find any significant changes in their immunologic status including interleukin 1 or 2 production.